Last reviewed · How we verify
Amlodipine camsylate
Amlodipine camsylate is a Dihydropyridine calcium channel blocker Small molecule drug developed by Organon and Co. It is currently FDA-approved for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).
Amlodipine camsylate blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased blood pressure.
Amlodipine camsylate blocks L-type calcium channels in vascular smooth muscle and cardiac tissue, reducing calcium influx and causing vasodilation and decreased blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina and vasospastic angina).
At a glance
| Generic name | Amlodipine camsylate |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
As a dihydropyridine calcium channel blocker, amlodipine camsylate selectively inhibits the inward movement of calcium ions through L-type calcium channels in the cell membrane of vascular smooth muscle cells. This reduces intracellular calcium concentration, preventing smooth muscle contraction and leading to vasodilation of coronary and peripheral arteries. The camsylate salt form is a specific formulation variant of amlodipine designed to improve solubility and bioavailability.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina and vasospastic angina)
Common side effects
- Peripheral edema
- Headache
- Flushing
- Fatigue
- Dizziness
- Palpitations
Key clinical trials
- Efficacy of Losartan + Amlodipine Compared to Amlodipine Alone in the Treatment of Uncontrolled High Blood Pressure (MK-0954F-399) (PHASE4)
- An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
- Diurnal Variation in Hypertensive Stroke Patients (PHASE4)
- Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amlodipine camsylate CI brief — competitive landscape report
- Amlodipine camsylate updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Amlodipine camsylate
What is Amlodipine camsylate?
How does Amlodipine camsylate work?
What is Amlodipine camsylate used for?
Who makes Amlodipine camsylate?
What drug class is Amlodipine camsylate in?
What development phase is Amlodipine camsylate in?
What are the side effects of Amlodipine camsylate?
What does Amlodipine camsylate target?
Related
- Drug class: All Dihydropyridine calcium channel blocker drugs
- Target: All drugs targeting L-type calcium channel
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris (chronic stable angina and vasospastic angina)
- Compare: Amlodipine camsylate vs similar drugs
- Pricing: Amlodipine camsylate cost, discount & access